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Abstract
Background: Hypoglycaemia, especially nocturnal, remains the main limiting factor of achieving good glycaemic
control in type 1 diabetes.
The effect of first generation long-acting insulin analogues in reducing nocturnal hypoglycaemia is well documented in
patient with type 1 diabetes. The effect of the newer long-acting insulin degludec on risk of nocturnal hypoglycaemia
remains undocumented in patients with type 1 diabetes and recurrent severe nocturnal hypoglycaemia.
The HypoDeg trial is designed to investigate whether insulin degludec in comparison with insulin glargine
U100 is superior in limiting the occurrence of nocturnal hypoglycaemia in patients with recurrent nocturnal
severe hypoglycaemia. This paper reports the study design of the HypoDeg trial.
Methods/design: A Danish investigator-initiated, prospective, randomised, open, blinded endpoint (PROBE),
multicentre, two-year cross-over study investigating the effect of insulin degludec versus insulin glargine U100
on frequency of nocturnal hypoglycaemia in patients with type 1 diabetes and one or more episodes of
nocturnal severe hypoglycaemia during the preceding two years as the major inclusion criteria. Patients are
randomised (1:1) to basal therapy with insulin degludec or insulin glargine. Insulin aspart is used as bolus
therapy in both treatment arms.
Discussion: In contrast to most other insulin studies the HypoDeg trial includes only patients at high risk of
hypoglycaemia. The HypoDeg trial will compare treatment with insulin degludec to insulin glargine U100 in
terms of risk of nocturnal hypoglycaemic episodes in patients with type 1 diabetes with the greatest potential
to benefit from near-physiological insulin replacement therapy. www.clinicaltrials.gov: NCT02192450.
Keywords: Type 1 diabetes, Nocturnal hypoglycaemia, Severe hypoglycaemia, Insulin degludec, Insulin
glargine, RCT
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Background
Hypoglycaemia is the main side-effect of insulin therapy
in type 1 diabetes and remains a major source of daily
concern for patients and their relatives. Nocturnal
hypoglycaemia, in particular, is a barrier against achieve-
ment of good glycaemic control as the fear of these epi-
sodes may impose inappropriate avoidance behaviour
resulting in overnight hyperglycaemia in many pa-
tients [1]. Reduction of nocturnal hypoglycaemia in
type 1 diabetes is therefore important to improve
overall glycaemic control.
Improved basal insulin therapy has consistently re-
sulted in reduced risk of nocturnal hypoglycaemia. Thus,
the first-generation insulin analogues insulin glargine U100
and insulin detemir both reduce nocturnal hypoglycaemia
by 26–53% compared to NPH insulin [2–4]. Insulin dete-
mir reduces the risk of nocturnal (severe and non-severe)
hypoglycaemia even in patients with type 1 diabetes and
recurrent severe hypoglycaemia [5–8]. However, nocturnal
hypoglycaemia remains a clinical challenge even with the
use of these insulin analogues.
Insulin degludec is a newer long-acting basal insulin
with a half-life of more than 24 h [9]. A recent study has
demonstrated a significantly lower day-to-day variability
than insulin glargine U100 – a coefficient of variation
(CV) of 21% versus 83%, respectively [10]. Two phase 3
trials and a meta-analysis involving patients with type 1
diabetes have demonstrated lower rates of nocturnal
hypoglycaemia with insulin degludec compared to insu-
lin glargine U100 [11–13]. Like most other insulin trials,
however, these trials only included participants at low
risk of hypoglycaemia and accordingly the absolute
risk reduction of nocturnal hypoglycaemia with insu-
lin degludec is small. The results from the phase 3
programme have been confirmed in the SWITCH1
trial, which included patients with type 1 diabetes and
increased risk of hypoglycaemia (e.g. people with im-
paired hypoglycaemia awareness, previous severe
hypoglycaemia, or impaired renal function) [14]. The
SWITCH1 trial did not specifically study people at
particular risk of severe nocturnal hypoglycaemia,
which may be those with the greatest potential to
benefit from insulin degludec. The effect of insulin
degludec in limiting nocturnal hypoglycaemia remains
undocumented in this high-risk type 1 diabetes
population.
The aim of this study is to compare the effect of insu-
lin degludec with insulin glargine U100 on risk of noc-
turnal hypoglycaemia in patients with previous severe
nocturnal hypoglycaemia.
Aims
The primary aim is to test the hypothesis that treatment
with insulin degludec as compared to insulin glargine
U100 results in lower risk of symptomatic nocturnal
hypoglycaemia in patients with type 1 diabetes and high
risk of severe nocturnal hypoglycaemia.
The secondary aims are – with reference to the
American Diabetes Association (ADA) criteria for classifi-
cation of hypoglycaemia [15] – to investigate the effect of
insulin degludec compared to insulin glargine U100 on:
– Any hypoglycaemic episode (symptomatic,
asymptomatic/silent, severe) analysed according to
severity and/or time of day
– Maintenance of baseline glycaemic control (HbA1c)
– Quality of life and depression/anxiety
Methods/design
Design, comparative treatment regimens and study
duration
A Danish investigator-initiated, cross-over, multi-
centre study conducted in a prospective, randomised,
open, blinded endpoint (PROBE) design (Fig. 1). Pa-
tients are randomised to treatment with basal-bolus
therapy with insulin degludec and insulin aspart (Tresiba®/
NovoRapid®) or insulin glargine U100 and insulin aspart
(Lantus®/NovoRapid®) in random order. Each treatment
period lasts for 12months. The first three months of each
treatment period is a run-in or cross-over phase to be used
n=175
0        3                      12      15                      24 months
Insulin degludec
Insulin glargine
Fig. 1 Study design. Endpoint assessment periods. Admission for overnight plasma glucose monitoring and/or 6 days of
ambulatory 24 h continuous glucose monitoring
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for insulin dose adjustment and stabilisation of treatment
regimens. Endpoints are assessed during the last nine
months of each treatment arm (Fig. 1). Optional ad-
missions for overnight plasma glucose measurements
and six days of ambulatory blinded continuous glu-
cose monitoring will be performed after 6 and 12
months in each treatment arm (Fig. 1).
Insulin doses will be adjusted according to the individual
patient’s need at the discretion of the individual physician.
Patients are instructed to perform and record 4-point self-
monitored blood glucose (SMBG) profiles twice per week
(before breakfast, before lunch, before dinner and at bed-
time). A treat-to-target design is deliberately not used in
order not to intervene with present glycaemic control and
everyday clinical practice, which in itself may interfere with
the risk of hypoglycaemia. We expect the individual patient
to present the best obtainable glycaemic control with respect
to risk of hypoglycaemia at inclusion, and we therefore strive
for maintenance of baseline glycaemic control in both treat-
ment periods. If, however, the glycaemic control is not ac-
ceptable we will strive for the best obtainable glycaemic
control in both treatment periods, taking the risk of
hypoglycaemia into account.
The HypoAna trial [5] showed significantly increased
rates of severe hypoglycaemia during run-in and cross-over
periods. Therefore, insulin doses are reduced at entrance
into both treatment arms. A 20% reduction in both basal
and bolus insulin dose is recommended when the patient
changes from one insulin regimen to another, irrespective
of the product. Rapid up titration by mandatory phone con-
sultations weekly at week 1, 2 and 4 is followed by ad hoc
titration at the investigators’ discretion.
The study is a once daily (QD) comparison between the
insulins with long duration of action, i.e. degludec and glar-
gine. Insulin degludec and insulin glargine U100 are admin-
istered subcutaneously in the thigh or in the abdominal
wall with the evening meal. Correct injection technique is
assured by a diabetes specialist nurse. The site of injection
should be changed within the same anatomical region to
avoid lipohypertrophy making insulin absorption more
unpredictable.
The study was approved by The Regional Committee
on Biomedical Research Ethics.
(#H-3-2014-101), the Danish Medicines Agency
(#2014071615) and the Danish Data Protection Agency
(I-suite no: 02945; #NOH-2014-018). The study is regis-
tered at www.eudract.ema.europe.eu (#2014–001942-24)
and at www.clinicaltrials.gov (# NCT02192450). The Study
is conducted in accordance with the Helsinki Declaration.
Participants
Pre-screening/pre-selection
Pre-screening/pre-selection approaches are used at the
participating outpatient clinics.
The primary approach is a questionnaire, which is
mailed to the patients or completed by the patients in
the clinic. Patients with one or more episodes of noctur-
nal severe hypoglycaemia in the preceeding two years
are interviewed by telephone to validate severity (need
for assistance from others) and causality of the events.
Screening, in- and exclusion criteria
Patients with one or more episodes of nocturnal severe
hypoglycaemia during the last two years are screened
(n = 154) according to in- and exclusion criteria.
The inclusion criteria are type 1 diabetes for more
than five years, one or more episodes of nocturnal severe
hypoglycaemia in the previous two years (defined as
need for third party assistance to restore blood glucose
level), age > 18 years, treatment with multiple dose insu-
lin injection (more than 2) or insulin pump allowing for
both human insulin and insulin analogues, a negative
pregnancy test, willingness to a once-daily (QD) regimen
concerning basal insulin, willingness to do SMBG and
keep a diary.
Exclusion criteria are history of primary or secondary
adrenal or growth hormone insufficiency, untreated
hypothyroidism, history of unstable angina or major
cardiovascular events, heart failure (New York Hart
Association (NYHA) class IV), history of malignancy un-
less a disease-free period exceeding five years, history of
alcohol or drug abuse, pregnancy or lactation, and
women of childbearing potential who are not using
chemical or mechanical contraception, HbA1c > 86
mmol/mol (10%), and shifting working hours. Criteria
for discontinuation are withdrawal of consent, pregnancy
or non-compliance with the study protocol as judged by
the investigator. Discontinuing patients are not
substituted, but data on discontinuing patients are in-
cluded in data analyses on an intention-to-treat basis.
Participants were included in the HypoDeg Trial from
January 2015 to February 2017. Last patient, last visit
expected in February 2019.
Randomisation
Patients are randomised 1:1 to insulin degludec or insu-
lin glargine. Treatment allocation will be obtained by a
web-based electronic case report file (CRF). The ran-
domisation will be in blocks of four on site. Treatment
allocation will not be blinded to patients or study
personnel caring for patients since insulin analogues dif-
fer in therir pharmacokinetic properties.
Visit procedures
Patients are seen in the outpatient clinics at Nordsjællands
Hospital, Steno Diabetes Center Copenhagen, Hvidovre
University Hospital, Køge Hospital, Odense University
Hospital, Copenhagen University Hospital (Rigshospitalet),
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Sydvestjysk Sygehus, Frederica Hospital, Aalborg Hospital
and Aarhus University Hospital for 10 visits.
Prior to any protocol-related procedures written in-
formed consent is obtained. At visit 0 (V0) patients are
screened for in- and exclusion criteria and eligible pa-
tients are scheduled for enrolment in the treatment
phase of the study. Information about demography, life-
style and medical history including diabetes treatment
history, diabetic complications and concomitant medica-
tion, is gathered at the screening visit. Frequencies of
episodes of nocturnal symptomatic hypoglycaemia dur-
ing the last month and severe hypoglycaemia within the
previous two years (overall and nocturnal) are reported
at V0 [16]. The patient’s insulin injection technique is
tested and corrected, if needed, and patterns of insulin
adjustment are clarified. A physical examination includ-
ing vital signs and body measurements completes the
screening visit.
At randomization (V1) the patients attend the clinic
after an overnight fast to enable fasting blood samples
(glucose and C-peptide). Urinary albumin excretion rate
is estimated in one overnight urine sample, and a bio-
bank of serum, plasma, DNA and urine samples are
established and stored at − 80 °C to permit subsequent
analyses of newly discovered relevant markers without
further discomfort to the patient.
Autonomic dysfunction is evaluated by the Vagustm
device (Medicus Engineering, Aarhus, Denmark), which
provides data on active tests of autonomic dysfunction
following guidelines and recommendations of ADA and
the European Association for the Study of Diabetes
(EASD) [17, 18]. A 12-lead electrocardiogram is re-
corded and visually assessed. State of hypoglycaemia
awareness is classified by three validated methods. [16,
19–21]. Four questionnaires about quality of life are
filled in: The EuroQol-5 dimension quality of life index
(EQ-5D-3 L), the Insulin Treatment Satisfaction Ques-
tionnaire (ITSQ), the Hypoglycaemic Confidence Scale
(HCS) and the Hypoglycemia Fear Survey (HFS).
Two questionnaires about depression and anxiety are
used: The Symptom Checklist (SCL-92) and Major
Depression Inventory (MDI) [22–24].
The procedures performed at the randomisation visit
(V1), except randomisation, are repeated at cross-over
(V5) and at the end of the study (V9). At every visit
(V1-V9) vital signs (blood pressure and pulse) and body
measurements (weight) are recorded and HbA1c is
measured.
Endpoint registration
Hypoglycaemia assessment
Hypoglycaemic events will be recorded during each
treatment period – during night-time and during day-
time. Night-time is defined from four hours after even-
ing bolus of short-acting insulin until time for actual
morning bolus insulin administration. Night-time will
also be analysed conventionally from 23:00 to 06:59 and
from 00:00 to 05:59 (Fig. 2). Daytime is defined conven-
tionally from 07:00 to 22:59 and from 06:00 to 23:59.
Morning 
bolus
Clock
hour
A
B
C
23:00 07:00
+ 4h after evening bolus
Fig. 2 Definition of night. a: night is defined as time from 4 h after evening bolus of short acting insulin until time for actual morning bolus
insulin administration. In the example shown the night is from 00:30 until 06:30, b: conventional definition of night from 23:00 to 06:59, c:
conventional definition of night from 00:00 to 05:59
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Data from the last nine months of each treatment arm
will be used for endpoint analyses.
Hypoglycaemic endpoints are defined according to the
latest ADA recommendations [15].
Documented mild symptomatic hypoglycaemia
Mild symptomatic hypoglycaemia is defined as an event
during which typical symptoms of hypoglycaemia are ac-
companied by a measured plasma glucose concentra-
tion ≤ 3.9 mmol/l and treated without assistance from
other persons. Patients are instructed and repeatedly en-
couraged to keep a diary on hypoglycaemia. Patients will
report all events of symptomatic hypoglycaemia includ-
ing date, time of episode, the accompanying measure-
ment of plasma glucose, symptoms, awake or asleep, and
time for last bolus insulin administration. In addition, all
episodes occurring during night-time must be reported
by telephone to a nurse within 24 h or first upcoming
weekday after the event. All possible nocturnal symp-
tomatic hypoglycaemic episodes will be adjudicated by
an independent endpoint committee consisting of dia-
betes specialists blinded to the individual patient’s insu-
lin regimen.
Asymptomatic hypoglycaemia
Asymptomatic hypoglycaemia is defined as an
event not accompanied by typical symptoms of
hypoglycaemia but with a measured plasma glucose
concentration ≤ 3.9 mmol/l. Assessment of asymptom-
atic hypoglycaemia is accommodated in the 4-point
SMBG profiles done twice a week and in the blinded
CGM data obtained after 6 and 12 months in each
treatment period.
Due to more recent hypoglycaemia guidelines [25]
analyses of nocturnal symptomatic hypoglycaemia and
any hypoglycaemic episode with a plasma glucose con-
centration ≤ 3.0 mmol/l are also planned.
Severe hypoglycaemia
Severe hypoglycaemia is a suspsected hypoglycaemic
event requiring treatment assistance from another per-
son. Carbohydrates, parenteral glucose or glucagon has
to be actively administered to restore plasma glucose to
normal. Plasma glucose measurements may or may not
be available during such an event. The need of treatment
assistance and adequate response to treatment is consid-
ered sufficient evidence that the event was induced by a
low plasma glucose concentration. These episodes may
be associated with sufficient neuroglycopenia to induce
seizure or coma [15]. The patient must report all events
of severe hypoglycaemia within 24 h by telephone to a
nurse. Like in daily clinical practice investigators must
encourage patients to report all episodes of severe
hypoglycaemia at the quarterly visits at the outpatient
clinics, hereby minimizing the risk of missing events.
A structured interview questionnaire will be applied to
all possible severe hypoglycaemic episodes in order to
validate episodes according to Whipple’s triad [26]. All
episodes will be adjudicated by an independent endpoint
committee consisting of diabetes specialists blinded to
the individual patient insulin regimen.
Additional hypoglycaemia assessment
In-hospital overnight glucose profiles
Patients are invited (optional) to stay overnight at
Nordsjællands Hospital Hillerød four times during the
study (after 6 and 12months in each treatment arm). At
the evening of the overnight stay the participants take
part of a standard meal. Afterwards the participants are
accommodated, and a venous line is inserted in an ante-
cubital vein. During the night, blinded samples for sub-
sequent plasma glucose measurements are drawn every
hour from the catheter, while the patient is asleep [27].
Continuous glucose monitoring (CGM)
Optionally interstitial glucose concentrations are
assessed twice for six days in each treatment arm using
the CGM device iPro®2 digital recorder, MMT-7741
(iPro2) with the Enlite® sensor (MMT-7008 (Glucose
sensor), Medtronic Minimed, Northridge, USA). The
sensor is mounted by a trained study nurse and the pa-
tient is instructed how to calibrate the device, using ca-
pillary glucose measurements. The device is mounted in
connection with visit 3, 5, 7 and 9 (after 6 and 12months
in each treatment arm).
After six days the glucose recorder is collected, and data
are uploaded into CareLink iPro Therapy Management
Software for Diabetes (CareLink iPro, MMT-7340) to gen-
erate reports and store data. These data remain blinded to
the investigators until the end of the study and are not
used to control glycaemic levels during the study period.
HbA1c assessment
At every visit to the outpatient clinic (excluding V0)
blood samples are drawn to measure HbA1c levels (ana-
lysed centrally at Nordsjællands Hospital).
Statistics
Power considerations
Rates and distribution of hypoglycaemic events are
much skewed and unpredictable [6, 28]. The occurrence
of hypoglycaemia is influenced by many factors, and by
engaging in a study rates of hypoglycaemia usually are
affected considerably.
Formal power calculations are therefore, not found
feasible.
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According to the power calculation and results from
the HypoAna trial with a significant relative difference
between treatment regimens of 30–40% concerning
both primary and secondary nocturnal endpoints [5, 6, 8],
we decided to include and randomise approximately 175
type 1 diabetes patients prone to severe hypoglycaemia
(i.e. one or more episodes of nocturnal severe
hypoglycaemia during the preceding two years).
Planned analyses
Intention-to-treat and per-protocol statistical analyses
will be conducted by the investigators, in close collabor-
ation with a statistician experienced in analysis of
hypoglycaemia data. Before the randomisation code will
be added to the cleaned dataset, a thorough plan for
statistical analyses will be elaborated and accepted by
the statistician and investigators. The cross–over design
makes it possible to accommodate the individual pa-
tient’s event parameters and continuous parameters. The
per-protocol analyses will include only patients who
have completed the first treatment period and at least 6
months of the second treatment period (cross-over plus
three months maintenance).
Endpoints will be compared between treatment groups
as an analysis of differences in rates during the last nine
months of each treatment arm. In the simplest model
this difference is assumed to be normally distributed and
tested as such under the assumption that the HbA1c
levels are comparable during the two treatment arms. If
necessary a more specific analysis in a negative binomial
distribution model and/or a Poisson model will be used
to describe the number of events through a suitable link
function as a linear function of individual patient levels,
treatment effects, treatment period, and mean HbA1c
level during endpoint assessment. Individual differences
in the observation period will be adjusted for in the
analyses.
For continuous parameters a co-variance analysis will
be conducted.
The level of statistical significance is chosen as p < 0.05
(two-sided).
Additional statistics
The obtained glycaemic control during the two treat-
ment regimens will be evaluated through comparisons of
HbA1c levels after 12 months’ treatment including fac-
tors corresponding to treatment, treatment period and
the individual patient level. Furthermore, SMBG profiles
will be evaluated in addition to quantification of glucose
variability during night-time and 6 days of CGM.
Laboratory analyses
HbA1c is measured at every visit (V1-V9). At V1 (ran-
domisation), V5 (cross-over) and V9 (end of study)
haemoglobin, haematocrit, plasma creatinine, plasma so-
dium, plasma potassium, total cholesterol, high and low-
density lipoprotein cholesterols, triglycerides, and thy-
roid-stimulating hormone (TSH), T4 and T3 are
measured.
Fasting C-peptide is only measured at randomisation
(V1) and concentrations below 20 pmol/l (= 0.02 nmol/L)
are considered C-peptide negative.
Urinary albumin excretion rate is determined in one
overnight urine sample at V1 and repeated after one year
at V5 and after 2 years at V9. This also applies to the
biobank samples (serum, plasma, DNA and urine) which
are gathered at V1, V5 and V9.
HbA1c is measured centrally at Nordsjællands Hospital
Hillerød using High Performance Liquid Chromatography
method on a Tosoh Automated Glycohemoglobin Analyzer.
All other analyses are performed locally by routine
methods.
Discussion
In contrast to almost all other studies in this field the
HypoDeg trial includes only patients who are
hypoglycaemia-prone. The HypoDeg trial will eluci-
date whether once-daily insulin degludec in compari-
son with once-daily insulin glargine U100 during
basal-bolus therapy is advantageous in limiting the
number of hypoglycaemic episodes in these patients
who may have the greatest benefit from optimized
basal insulin therapy.
This insulin trial is one of a few to systematically
evaluate the risk of hypoglycaemia by simultaneous adju-
dication of events, reporting in diaries and observation
by CGM [5–7].
The results may have a direct evidence-based impact
on the patients and their health care professionals in
choice of basal therapy.
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